Peripheral T-Cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma (PTCL) Market

Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas, which develop from mature T-cells and natural killer (NK) cells. PTCL is classified as a subtype of non-Hodgkin’s lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. PTCL specifically affects T-cells and results when T-cells develop and increase abnormally. The most common subtype is called PTCL-not-otherwise specified (PTCL-NOS) and is most frequently diagnosed in individuals living in North America and Europe.

Peripheral T-Cell Lymphoma Epidemiological Segmentation 

The Epidemiological Segmentation of Peripheral T-Cell Lymphoma in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of Peripheral T-cell Lymphoma (PTCL)
  • Stage-Specific Incident Cases of Peripheral T-cell Lymphoma (PTCL)
  • Subtype-Specific Incident Cases of Peripheral T-cell Lymphoma (PTCL)

Peripheral T-Cell Lymphoma Epidemiology 

  • PTCL accounts for 10–15% of all non-Hodgkin lymphomas worldwide.
  • The total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM in 2017 was 16,298
  • PTCL accounts for 7–15% of NHLs in the United States and EU-5 countries
  • EU5 countries occupied around 28.48% of the patient pool amongst 7MM in 2017

Peripheral T-Cell Lymphoma Market

The market size of PTCL in 7MM in 2017 was USD 815.38 Million

Peripheral T-Cell Lymphoma Market Drivers

  • Use of Combination Therapies
  • Upcoming novel therapies in the pipeline for the treatment of PTCL
  • An upsurge in Research and Development


Peripheral T-Cell Lymphoma Market Barriers

  • Low rates of incidence
  • Less expertise in diagnosis and rarity of PTCL subtypes
  • Lack of awareness

Peripheral T-Cell Lymphoma Emerging Drugs

The Emerging drugs of the Peripheral T-Cell Lymphoma market are 

  • Denileukin diftitox
  • SP-02 (Darinaparsin, ZIO-101)
  • Fenretinide (4-HPR)
  • Tipifarnib
  • HBI-8000
  • COPIKTRA (Duvelisib)
  • Genolimzumab (GB226)
  • Azacitidine (CC-486)
  • Tislelizumab
  • Lacutamab/IPH4102
  • AFM13
  • Opdivo (nivolumab) + Cabiralizumab
  • Bavencio (avelumab)
  • Keytruda (pembrolizumab): STI-3031/IMC-001
  • ALRN 6924
  • Masitinib
  • Ruxolitinib
  • Aplidin (plitidepsin)

ASTX660: And many others. 

Peripheral T-Cell Lymphoma Key Players

The key players in the Peripheral T-Cell Lymphoma market are

  • Eisai
  • Solasia Pharma
  • CerRx
  • Kura Oncology
  • HUYA Bioscience International/Quintiles, Inc
  • Verastem
  • Genor Biopharma
  • Celgene Corporation
  • BeiGene
  • Innate Pharma
  • Affimed GmbH
  • Bristol-Myers Squibb
  • Pfizer
  • Merck Sharp & Dohme Corp.
  • Sorrento Therapeutics
  • Aileron Therapeutics
  • AB Science
  • Incyte Corporation/Novartis
  • PharmaMar
  • Otsuka Pharmaceutical
  • Astex Pharmaceuticals

And many others.